A Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With Metastatic Castration-Resistant Prostate Cancer

Conditions: Metastatic Castration-resistant Prostate Cancer (mCRPC) Interventions: Drug: YL201 for Injection Sponsors: MediLink Therapeutics (Suzhou) Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials